This Week in Nephrology — May 21, 2026

Welcome to This Week in Nephrology. This week we're covering 10 notable papers spanning new therapeutic approaches in complex kidney diseases, innovations in diagnostics, and key considerations for transplantation in older adults. Let's dive in.

Advances in Therapeutics for Complex Kidney Disease This week brings several important updates on managing complex kidney conditions, from amyloidosis and Fabry disease to choosing the right medication for patients on dialysis. First, a clinically vital question for any nephrologist managing patients on hemodialysis: does the dialyzability of a beta-blocker matter? A new study in the Journal of the American Society of Nephrology provides a compelling answer [5]. Using United States Renal Data System information and a robust instrumental variable analysis to emulate a target trial, investigators compared outcomes between patients starting hemodialysis on nondialyzable versus dialyzable beta-blockers. The cohort included over 40,000 patients. The primary outcome was a composite of major adverse cardiovascular events, or MACE, including myocardial infarction, stroke, and all-cause mortality. The results were consistent and significant. Compared to dialyzable agents, nondialyzable beta-blockers were associated with a lower risk of MACE at all time points. The hazard ratio was 0.82 at 6 months, 0.85 at 1 year, and 0.90 at 3 years. This translates to a roughly 10 to 18 percent lower risk of MACE for patients on nondialyzable agents. The benefit was seen across all individual components of the composite outcome and was particularly notable in the high-risk period immediately following dialysis initiation. This study provides strong evidence to favor nondialyzable beta-blockers, such as carvedilol or metoprolol, in this population.

Next, two papers from Nephrology, Dialysis, Transplantation address treatment for rare but severe proteinuric diseases. The first compares daratumumab monotherapy to older bortezomib-based regimens for frail, non-transplant-eligible patients with biopsy-proven renal AL amyloidosis [6]. In this single-center study of 31 patients, those in the prospective daratumumab cohort achieved significantly higher response rates. The hematologic response rate was 93% with daratumumab versus 57% with bortezomib. Even more striking, the renal response rate was 71% with daratumumab compared to just 35% with bortezomib. While overall survival did not reach statistical significance in this small sample, the trend favored daratumumab, with 79% survival at last follow-up compared to 47% in the historical bortezomib group. Repeat biopsies also showed stabilization or regression of amyloid deposits in over 60% of daratumumab-treated patients, versus only 20% in the bortezomib group. These findings support using anti-CD38 therapy with daratumumab early in this vulnerable patient population.

The second NDT paper explores a novel application for a well-known drug class [7]. In a prospective, proof-of-concept study, investigators administered the dual GIP/GLP-1 receptor agonist tirzepatide to 15 overweight, non-diabetic patients with Fabry disease who had persistent proteinuria despite optimized standard therapy. The results were impressive. Over 6 months, mean 24-hour proteinuria fell by nearly 70%, from 1.1 grams to 0.35 grams, with two-thirds of patients achieving a level below the 0.5 gram per day threshold. This profound antiproteinuric effect occurred alongside significant weight loss but, importantly, with a stable eGFR. Furthermore, cardiac biomarkers like NT-proBNP and high-sensitivity troponin T also showed significant reductions. This suggests that GIP/GLP-1 receptor agonists may offer a new, multi-pathway nephroprotective strategy for Fabry disease, acting beyond substrate reduction and RAS inhibition.

Transplantation and High-Risk Populations Two papers this week provide crucial data for managing patients in high-risk scenarios: older adults considering transplantation and pregnant women with new-onset kidney disease. A common and difficult counseling point is the true benefit of kidney transplantation for older adults. Using a target trial emulation framework, a study in the American Journal of Kidney Diseases analyzed data for over 2,600 transplant-eligible adults aged 75 years or older [1]. The study compared survival for those who received a deceased donor kidney transplant versus those who remained on dialysis. The findings provide a critical benchmark for patient counseling. In the first 90 days after transplant, recipients faced a more than doubled risk of mortality compared to those on dialysis. The survival curves crossed at a break-even point of 3 years, where survival was equivalent between the two groups. It was only after this point that a clear benefit emerged. By 5 years, transplantation conferred a survival advantage of 111 days. The authors conclude that while a survival benefit exists, it is modest and emerges late, making continued dialysis a reasonable alternative that should be discussed as part of individualized decision-making.

In another high-risk population, a French nationwide survey published in Nephrology, Dialysis, Transplantation offers reassuring data on the safety and utility of kidney biopsy during pregnancy [10]. The study reviewed 76 patients who underwent a native kidney biopsy between 2006 and 2025, mostly for nephrotic syndrome or non-nephrotic proteinuria. The median gestational age at biopsy was 13.5 weeks. The procedure had a very high diagnostic yield, providing a specific diagnosis in nearly 95% of cases, with lupus nephritis, FSGS, and membranous nephropathy being the most common findings. Importantly, the procedure was safe, with only one patient experiencing bleeding that required a transfusion. The biopsy had a major therapeutic impact, leading to the initiation of specific treatment in over 63% of patients. While the cohort had high rates of adverse obstetric outcomes like preeclampsia and preterm birth, this is likely attributable to the severity of the underlying kidney disease rather than the biopsy itself. The findings support the use of kidney biopsy in the first two trimesters when a diagnosis is needed to guide management.

Diagnostics and Basic Science Insights Shifting to diagnostics and the science that underpins them, a paper in Science Translational Medicine introduces a potential noninvasive method for detecting and staging kidney fibrosis [4]. Current clinical metrics like eGFR and serum creatinine are poor at quantifying fibrosis. Researchers developed fibrogenesis sensing reporters, or FSRs, which are injectable agents that are cleared by the kidneys. In a fibrotic kidney, two enzymes—lysl oxidase and transglutaminase 2, or TG2—are upregulated. The FSR is engineered to be activated by these enzymes, causing it to fluoresce. This allows for both in vivo imaging and, more practically, a urine-based assay. In a clinical cohort of 35 individuals, the FSR-based urinalysis could distinguish patients with CKD from healthy controls with high sensitivity and specificity. Crucially, it could also discriminate between patients with histologically mild versus severe fibrosis, a task that traditional markers like eGFR and creatinine could not accomplish. This activatable reporter technology holds translational potential for earlier identification and stratification of patients with CKD.

Underpinning all our clinical work is basic science that reveals disease mechanisms. A study in the Journal of the American Society of Nephrology investigated the role of a protein called Cyclin G-Associated Kinase, or GAK, in podocytes [9]. Researchers found that mice with podocyte-specific loss of GAK developed severe proteinuria and kidney failure. At the cellular level, the loss of GAK led to impaired lysosomal function, causing an accumulation of autophagic vesicles. This lysosomal dysfunction triggered the podocytes to adopt immune-like properties, producing the pro-inflammatory cytokine IL-11. This work identifies GAK, and specifically its C-terminal domains, as a crucial player in maintaining podocyte homeostasis and suggests that lysosomal dysfunction can be a direct trigger for an inflammatory state in podocytes, contributing to kidney injury.

Shaping the Future of Nephrology Research and Policy Finally, we'll look at three papers that are not about a single intervention, but about building a stronger foundation for our specialty. First, from Nature Reviews Nephrology, an expert panel from the Clinical Genome Resource, or ClinGen, has provided a comprehensive curation of gene-disease relationships for glomerular phenotypes [2]. They evaluated 57 potential relationships and classified 34 as having definitive evidence, while others had moderate, limited, or insufficient evidence. This work is critical for standardizing diagnostic genetic testing panels for glomerular disease, ensuring that clinicians are testing for genes with robust links to pathology.

Second, a paper in the BMJ addresses a challenge in clinical trial methodology [3]. The authors present the CRT-Estimands Framework, a consensus-based extension of existing guidelines for defining research questions in cluster randomized trials. While this is highly technical, its goal is practical: to ensure that when we randomize by clinic or dialysis unit instead of by individual patient, the research question and the results are described with absolute clarity. This improves our ability to interpret and apply the findings from these complex trials.

Lastly, a Health Policy paper in The Lancet provides a practical framework for implementing the ambitious goals set by the 2025 World Health Assembly resolution on kidney health [8]. Authored by leaders in global kidney health, it offers a roadmap for governments and partners to operationalize commitments on prevention, early detection, primary care integration, and access to kidney replacement therapy. It emphasizes the need for political commitment, accountability, and mechanisms to measure progress, drawing on lessons learned from other non-communicable disease programs. This paper serves as a vital tool for turning global policy into local action to improve kidney health for millions.

Editor's Pick If you only have time for one paper this week, make it the study in the Journal of the American Society of Nephrology on beta-blocker dialyzability [5]. It addresses a common, practical clinical question with a robust analysis and provides a clear, actionable takeaway: nondialyzable beta-blockers are associated with better cardiovascular outcomes in patients starting hemodialysis.

Clinical Bottom Line Here are the key takeaways from this week in Nephrology. First: For hemodialysis patients requiring a beta-blocker, prefer a nondialyzable agent like carvedilol or metoprolol, as they are associated with a significantly lower risk of major adverse cardiovascular events. Second: In frail, non-transplant-eligible patients with renal AL amyloidosis, daratumumab monotherapy appears superior to bortezomib-based regimens, yielding higher hematologic and renal response rates. Third: When counseling patients aged 75 or older about deceased donor kidney transplantation, be clear that the survival benefit does not emerge until about 3 years post-transplant and the overall 5-year advantage is modest, at around 111 days. Fourth: Kidney biopsy during the first or second trimester of pregnancy is a relatively safe procedure with a high diagnostic yield that frequently alters management, making it a valuable tool for unexplained, severe kidney disease in this population. And finally: Dual GIP/GLP-1 receptor agonists like tirzepatide may have a role in reducing residual proteinuria in non-diabetic conditions like Fabry disease, representing a potential new nephroprotective strategy beyond standard therapies.

That's your roundup for This Week in Nephrology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.